AAAAAA
Results:
1-11
|
Results: 11
Authors:
HARTMANN JT
HARSTRICK A
DAIKELER T
KOLLMANNSBERGER C
MULLER C
SEEBER S
KANZ L
BOKEMEYER C
Citation: Jt. Hartmann et al., PHASE-II STUDY OF CONTINUOUS 120 H INFUSION OF MITOMYCIN-C AS SALVAGECHEMOTHERAPY IN PATIENTS WITH PROGRESSIVE OR RAPIDLY RECURRENT COLORECTAL-CANCER, Anti-cancer drugs, 9(5), 1998, pp. 427-431
Authors:
KOLLMANNSBERGER C
QUIETZCH D
CLEMENS M
LAMPE C
LINGENFELSER T
HARTMANN JT
KANZ L
BOKEMEYER C
Citation: C. Kollmannsberger et al., A PHASE-II TRIAL OF PACLITAXEL, CISPLATIN, AND WEEKLY 24 H INFUSION OF 5-FLUOROURACIL (5-FU) FOLINIC ACID (FA) IN PATIENTS (PTS) WITH ADVANCED GASTRIC-CANCER/, Annals of oncology, 9, 1998, pp. 229-229
Authors:
KOLLMANNSBERGER C
BOYER J
DROZ JP
HARSTRICK A
HARTMANN JT
BIRON P
FLECHON A
SCHOFFSKI P
KUCZYK M
SCHMOLL HJ
KANZ L
BOKEMEYER C
Citation: C. Kollmannsberger et al., SECONDARY LEUKEMIA FOLLOWING HIGH CUMULATIVE DOSES OF ETOPOSIDE IN PATIENTS TREATED FOR ADVANCED GERM-CELL TUMORS, Journal of clinical oncology, 16(10), 1998, pp. 3386-3391
Authors:
BOKEMEYER C
HARTMANN JT
KUCZYK MA
TRUSS MC
KOLLMANNSBERGER C
BEYER J
JONAS U
KANZ L
Citation: C. Bokemeyer et al., RECENT STRATEGIES FOR THE USE OF PACLITAXEL IN THE TREATMENT OF UROLOGICAL MALIGNANCIES, World journal of urology, 16(2), 1998, pp. 155-162
Authors:
BRUGGER W
DIERKESMANN R
TOOMES H
ENGELHARDT R
HASSE J
PRESSLER K
KOLLMANNSBERGER C
SCHUMACHER M
FROMMHOLD H
BAMBERG M
KANZ L
Citation: W. Brugger et al., MULTICENTER RANDOMIZED PHASE-III STUDY EVALUATING THE ROLE OF HIGH-DOSE CHEMOTHERAPY AND PERIPHERAL-BLOOD PROGENITOR-CELL SUPPORT IN PATIENTS WITH LIMITED-STAGE SMALL-CELL LUNG-CANCER, Onkologie, 21, 1998, pp. 12-14
Authors:
KOLLMANNSBERGER C
PETERS HD
FINK U
Citation: C. Kollmannsberger et al., CHEMOTHERAPY IN ADVANCED PANCREATIC ADENOCARCINOMA, Cancer treatment reviews, 24(2), 1998, pp. 133-156
Authors:
KOLLMANNSBERGER C
HARTMANN JT
KANZ L
BOKEMEYER C
Citation: C. Kollmannsberger et al., RISK OF SECONDARY MYELOID-LEUKEMIA AND MYELODYSPLASTIC SYNDROME FOLLOWING STANDARD-DOSE CHEMOTHERAPY OR HIGH-DOSE CHEMOTHERAPY WITH STEM-CELL SUPPORT IN PATIENTS WITH POTENTIALLY CURABLE MALIGNANCIES, Journal of cancer research and clinical oncology, 124(3-4), 1998, pp. 207-214
Authors:
BOKEMEYER C
BERGER CC
HARTMANN JT
KOLLMANNSBERGER C
SCHMOLL HJ
KUCZYK MA
KANZ L
Citation: C. Bokemeyer et al., ANALYSIS OF RISK-FACTORS FOR CISPLATIN-INDUCED OTOTOXICITY IN PATIENTS WITH TESTICULAR CANCER, British Journal of Cancer, 77(8), 1998, pp. 1355-1362
Authors:
HARTMANN JT
KOHNE CH
SCHMOLL HJ
KOLLMANNSBERGER C
KANZ L
BOKEMEYER C
Citation: Jt. Hartmann et al., PHASE-II STUDY OF 24 HOURS-INFUSION OF 5-FLUOROURACIL AND HIGH-DOSE FOLINIC ACID IN PATIENTS WITH PROGRESSIVE OR RECURRENT COLORECTAL-CANCER (CRC), European journal of cancer, 33, 1997, pp. 759-759
Authors:
BOKEMEYER C
LAMPE CS
CLEMENS MR
HARTMANN JT
QUIETZSCH D
FORKMANN L
KOLLMANNSBERGER C
KANZ L
Citation: C. Bokemeyer et al., A PHASE-II TRIAL OF PACLITAXEL AND WEEKLY 24 H INFUSION OF 5-FLUOROURACIL FOLINIC ACID IN PATIENTS WITH ADVANCED GASTRIC-CANCER, Anti-cancer drugs, 8(4), 1997, pp. 396-399
Authors:
BRUGGER W
GRAMATZKI M
KOLLMANNSBERGER C
KIEFER T
MERTELSMANN R
KANZ L
Citation: W. Brugger et al., EARLY HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS PERIPHERAL-BLOOD PROGENITOR-CELL (PBPC) TRANSPLANTATION IN PATIENTS WITH HIGH-RISK, AGGRESSIVENON-HODGKINS-LYMPHOMA, Blood, 84(10), 1994, pp. 10000234-10000234
Risultati:
1-11
|